Entrigue Surgical, a San Antonio, Tex., medical-devices maker, raised $6.3 million in a first funding round, VentureWire reports (subscription requires), crediting the San Antonio Express-News (no link available). Vertical Group and Prism VentureWorks provided the investment.

According to Entrigue’s bare-bones Web site — which features little more than a quick marketing blurb and a clock counting down to a “revolution” promised 65 days from now — and the Express-News item, Entrigue is developing devices and biomaterials for head and neck surgeons designed for ear, nose and throat applications.

A few more details from the News-Express item, which I had to dig up in Nexis/Lexis:

Fred Dinger III is in demand. Last July, Dinger, then CEO of Osteobiologics Inc., sold the medical device company to London-based Smith & Nephew PLC, an orthopedic biomedical firm, for $72.3 million….

A few months after selling Osteobiologics, Dinger formed Concept to Market, known as C2M, with four former co-workers. C2M is a biotechnology-consulting firm that works for Warburg Pincus in New York and The Vertical Group in New Jersey. C2M advises other biotechnology companies nationwide. Yet Dinger wasn’t content with just advising others. He wanted to run a company in San Antonio.

That’s when Entrigue Surgical Inc., a Boston-based startup focused on head and neck surgery, tried to recruit him as CEO. He told its officers that if they moved it to San Antonio, his team would run it. They agreed. Entrigue Surgical, with 10 employees, develops biomaterials and medical instruments for head and neck surgeons. Dinger just raised $6.3 million in venture capital for Entrigue Surgical.

There aren’t too many companies focused on otaryngology devices. One other is Menlo Park, Calif.-based Acclarent, a designer of a sinus-treatment device, which we last wrote about here.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.